Accenture Invests in Ryght AI to Accelerate Clinical Trial Execution Through Agentic AI Platform
Key Insights
Accenture has made a strategic investment through Accenture Ventures (search) in Ryght AI (search), a platform provider that modernizes clinical research design and execution for life sciences companies.
Ryght AI (search)'s AI Site Twin platform creates dynamic digital replicas of clinical research sites worldwide, incorporating historical performance data, patient demographics, and real-time operational insights to streamline site selection and patient enrollment.
The collaboration aims to accelerate three critical stages of drug development: trial feasibility assessment, site selection, and patient recruitment, helping bring new treatments to patients faster.
Accenture has made a strategic investment in Ryght AI (search), a platform provider focused on modernizing clinical research design and execution across the life sciences industry. The investment, made through Accenture Ventures (search), aims to help life sciences and clinical research organizations accelerate drug development timelines by combining agentic AI capabilities with enterprise technology solutions.
Addressing Clinical Trial Complexity
The clinical trial process has become increasingly complex, creating significant bottlenecks that delay the introduction of promising therapies. Manual site selection processes can add weeks or months to each study, contributing to rising development costs and extended timelines for bringing new treatments to patients. These challenges particularly impact site selection and patient enrollment, two critical components of successful clinical trial execution.
AI Site Twin Technology
Ryght AI (search) addresses these challenges through its AI Site Twin platform, which creates dynamic digital replicas of clinical research sites worldwide. These digital models capture historical performance data, patient demographics, regulatory considerations, and real-time operational insights. The platform enables sponsors and contract research organizations to more efficiently identify suitable trial sites, improve enrollment forecasting accuracy, and streamline site activation workflows.
The SOC Type 2-compliant platform is designed to enhance efficiency by fostering seamless, real-time communication between sponsors, contract research organizations, and research sites throughout the clinical trial lifecycle.
Strategic Collaboration
The partnership combines Accenture's industry expertise, technology services, and data engineering capabilities with Ryght AI (search)'s domain-specific agentic AI platform. The collaboration specifically targets three critical stages of drug development: trial feasibility assessment, site selection, and patient recruitment. The companies expect the integration of agentic AI into these workflows to improve decision-making, operational efficiency, and trial outcomes at scale.
"Generative and agentic AI are transforming the foundation of clinical research," said Petra Jantzer, PhD, senior managing director and global lead of Life Sciences at Accenture. "With our investment in Ryght AI (search), we're giving our life sciences clients the ability to fully leverage operational and scientific data and bring life-changing therapies to market faster, more efficiently and with greater precision."
Simon Arkell, CEO of Ryght AI (search), emphasized the global scale potential of the partnership: "This partnership allows Ryght AI to extend the impact and adoption of our technology to a global scale. Together, we can help life science companies reimagine how clinical trials are planned, launched and managed—accelerating the journey from discovery to treatment."
Broader Investment Strategy
This investment represents the latest in Accenture's series of investments in innovative biotechnology startups that use transformational technology to accelerate clinical trials and drug discovery efforts. Recent investments include 1910 Genetics (search), Turbine (search), and Earli (search), each focused on advancing AI-enabled approaches across different aspects of biopharmaceutical research and development.
Financial terms of the Ryght AI (search) investment were not disclosed. The collaboration is positioned to help life sciences organizations leverage operational and scientific data more effectively while reducing friction across study startup processes and enabling more data-driven planning throughout clinical trial execution.